Loading
A phase 1/2 trial of SYS6043 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07415863 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 820 participants planned, started 2024-12-30 and due to reach its primary completion in 2027-12-30. Interventions recorded: SYS6043.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/